Literature DB >> 24972772

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.

Dominik Dytfeld1, Jagoda Jasielec2, Kent A Griffith3, Daniel Lebovic3, David H Vesole4, Sundar Jagannath5, Ammar Al-Zoubi3, Tara Anderson3, Kristen Detweiler-Short3, Keith Stockerl-Goldstein6, Asra Ahmed3, Terri Jobkar3, Diane E Durecki3, Kathryn McDonnell2, Melissa Mietzel3, Daniel Couriel3, Mark Kaminski3, Ravi Vij6, Andrzej J Jakubowiak7.   

Abstract

Entities:  

Keywords:  carfilzomib; elderly; lenalidomide; low-dose dexamethasone; multiple myeloma; newly diagnosed

Mesh：

Substances：

Year:  2014        PMID： 24972772      PMCID： PMC4562550          DOI： 10.3324/haematol.2014.110395

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

3.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Authors:  Antonio Palumbo; Sara Bringhen; Alessandra Larocca; Davide Rossi; Francesco Di Raimondo; Valeria Magarotto; Francesca Patriarca; Anna Levi; Giulia Benevolo; Iolanda Donatella Vincelli; Mariella Grasso; Luca Franceschini; Daniela Gottardi; Renato Zambello; Vittorio Montefusco; Antonietta Pia Falcone; Paola Omedé; Roberto Marasca; Fortunato Morabito; Roberto Mina; Tommasina Guglielmelli; Chiara Nozzoli; Roberto Passera; Gianluca Gaidano; Massimo Offidani; Roberto Ria; Maria Teresa Petrucci; Pellegrino Musto; Mario Boccadoro; Michele Cavo
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

4.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal:  Lancet Oncol       Date:  2010-08-23       Impact factor: 41.316

5.  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

Authors:  P Leif Bergsagel; María-Victoria Mateos; Norma C Gutierrez; S Vincent Rajkumar; Jesús F San Miguel
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

6.  Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.

Authors:  Francesca Gay; Alessandra Larocca; Pierre Wijermans; Federica Cavallo; Davide Rossi; Ron Schaafsma; Mariella Genuardi; Alessandra Romano; Anna Marina Liberati; Agostina Siniscalchi; Maria T Petrucci; Chiara Nozzoli; Francesca Patriarca; Massimo Offidani; Roberto Ria; Paola Omedè; Benedetto Bruno; Roberto Passera; Pellegrino Musto; Mario Boccadoro; Pieter Sonneveld; Antonio Palumbo
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

7.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Authors:  Thierry Facon; Jean Yves Mary; Cyrille Hulin; Lotfi Benboubker; Michel Attal; Brigitte Pegourie; Marc Renaud; Jean Luc Harousseau; Gaëlle Guillerm; Carine Chaleteix; Mamoun Dib; Laurent Voillat; Hervé Maisonneuve; Jacques Troncy; Véronique Dorvaux; Mathieu Monconduit; Claude Martin; Philippe Casassus; Jérôme Jaubert; Henry Jardel; Chantal Doyen; Brigitte Kolb; Bruno Anglaret; Bernard Grosbois; Ibrahim Yakoub-Agha; Claire Mathiot; Hervé Avet-Loiseau
Journal:  Lancet       Date:  2007-10-06       Impact factor: 79.321

8.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

9.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

Authors:  David Siegel; Thomas Martin; Ajay Nooka; R Donald Harvey; Ravi Vij; Ruben Niesvizky; Ashraf Z Badros; Sundar Jagannath; Leanne McCulloch; Kanya Rajangam; Sagar Lonial
Journal:  Haematologica       Date:  2013-08-09       Impact factor: 9.941

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245
View more
  17 in total

Review 1.  Integration of Novel Agents into the Care of Patients with Multiple Myeloma.

Authors:  Robert Z Orlowski; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2016-11-14       Impact factor: 12.531

Review 2.  Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

Authors:  Adeela Mushtaq; Vikas Kapoor; Azka Latif; Ahmad Iftikhar; Umar Zahid; Ali McBride; Ivo Abraham; Irbaz Bin Riaz; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2018-03-02       Impact factor: 6.312

3.  NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Frederic J Reu; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2016-04       Impact factor: 11.908

Review 4.  Managing multiple myeloma in elderly patients.

Authors:  Evan Diamond; Oscar B Lahoud; Heather Landau
Journal:  Leuk Lymphoma       Date:  2017-08-28

Review 5.  Management of multiple myeloma in the newly diagnosed patient.

Authors:  María-Victoria Mateos; Jesús F San Miguel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Approach to the Older Adult With Multiple Myeloma.

Authors:  Roberto Mina; Sara Bringhen; Tanya M Wildes; Sonja Zweegman; Ashley E Rosko
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 7.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

8.  Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.

Authors:  Isamu Sugiura; Kenshi Suzuki; Masaki Ri; Takaaki Chou; Naoki Takezako; Kazutaka Sunami; Tadao Ishida; Tohru Izumi; Shuji Ozaki; Yoshihisa Shumiya; Shinsuke Iida
Journal:  Int J Hematol       Date:  2019-10-29       Impact factor: 2.490

9.  Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Seema Singhal; Clayton Smith; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908

10.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Authors:  Juan-Jose Lahuerta; Bruno Paiva; Maria-Belen Vidriales; Lourdes Cordón; Maria-Teresa Cedena; Noemi Puig; Joaquin Martinez-Lopez; Laura Rosiñol; Norma C Gutierrez; María-Luisa Martín-Ramos; Albert Oriol; Ana-Isabel Teruel; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Miguel T Hernandez; Luis Palomera; Rafael Martinez; Alejandro Martin; Adrian Alegre; Javier De la Rubia; Alberto Orfao; María-Victoria Mateos; Joan Blade; Jesus F San-Miguel
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.